Lunesta (Eszopiclone): History and Development

Eszopiclone is the generic name for the medication marketed under the brand name Lunesta, a prescription-only cyclopyrrolone hypnotic that acts as a positive allosteric modulator at GABA-A receptors. It is chemically related to, but not identical to, racemic zopiclone (brand name Imovane outside the United States) and belongs to the same broad "Z-drug" non-benzodiazepine hypnotic class as zolpidem (Ambien) and zaleplon (Sonata). This article traces how eszopiclone was developed, how the FDA evaluated it, and what has changed in its labeling since 2004.

The core historical fact worth knowing: eszopiclone is the isolated, more receptor-active enantiomer of zopiclone, a drug that was never approved for sale in the United States, and when the FDA approved eszopiclone in December 2004 it did so without the short-term-use restriction that applied to earlier hypnotics, a decision built on a longer-duration trial program than had previously been submitted for this drug class. That regulatory difference reflects what was tested, not necessarily a proven safety advantage over other hypnotics, and readers should not treat it as evidence that eszopiclone carries lower long-term risk than alternatives that were simply never studied over the same duration.

What eszopiclone is derived from

Racemic zopiclone was introduced in France in 1986 and subsequently marketed in dozens of countries. It is a mixture of two mirror-image molecules, the S-enantiomer and the R-enantiomer. Preclinical binding work reported that the S-enantiomer has substantially greater affinity for the GABA-A benzodiazepine binding site than the R-enantiomer, which made isolating the S-form a rational basis for a separate drug development program. Sepracor Inc., a Massachusetts company built around chiral drug chemistry, pursued this isolation in the late 1990s and filed for the S-enantiomer as a new chemical entity. Because racemic zopiclone itself was never approved in the United States, the FDA reviewed eszopiclone as an independent new drug application rather than as a reformulation of an existing U.S. product.

This kind of "chiral switch" also produced esomeprazole from omeprazole and escitalopram from citalopram in roughly the same period, though those cases differ in that the parent racemate was already FDA-approved in the U.S. market.

How eszopiclone works, and how that differs from benzodiazepines

Eszopiclone enhances GABA-A receptor chloride conductance, producing sedation and reduced cortical arousal. Its binding site overlaps with the classical benzodiazepine binding pocket but is not identical to it. Pharmacology literature on GABA-A receptor subtypes describes eszopiclone as having relatively greater activity at alpha-2 and alpha-3 subunit-containing receptors compared with older, less selective benzodiazepines, which has been proposed as a partial explanation for a more favorable next-day cognitive profile at therapeutic doses. Alpha-1 subunit activity, which is more closely linked to sedation itself, is still present. This selectivity difference is a plausible mechanistic explanation drawn from receptor pharmacology; it is not the same as a head-to-head clinical trial proving fewer next-day effects than a specific comparator, and readers should not treat receptor-binding selectivity alone as a guarantee of clinical superiority.

Eszopiclone's elimination half-life is commonly cited as around 6 hours in healthy adults, longer than zaleplon (roughly 1 hour) and longer than immediate-release zolpidem (roughly 2.5 hours). A longer half-life is consistent with a drug being useful for both sleep-onset and sleep-maintenance complaints, but half-life alone does not establish clinical effectiveness for either; that requires trial data specific to the drug and endpoint.

The clinical trial program behind the "no duration limit" label

Sepracor's development program for eszopiclone reportedly included short-term trials (roughly 2 and 6 weeks) and a longer randomized, double-blind, placebo-controlled trial extending to 6 months, along with an open-label extension. The 6-month trial, led by Andrew Krystal and colleagues and published in the journal Sleep in 2003, is widely cited in the medical literature as the pivotal study behind the FDA's decision to approve eszopiclone without the short-term-use restriction that applied to earlier hypnotics such as zolpidem, zaleplon, and triazolam. Separately, polysomnographic studies and a dedicated trial in adults aged 65 to 86 are described in secondary sources as supporting both objective sleep-latency findings and the lower elderly starting dose.

Because the specific PubMed identifiers historically attached to these trials in earlier versions of this article could not be independently confirmed as pointing to the correct papers, this draft does not carry forward exact effect-size numbers (for example, precise minute-by-minute reductions in sleep latency or percentage improvements in sleep quality) as verified figures. Anyone citing exact numeric results from the Krystal 2003 Sleep trial, the associated polysomnographic study, or the elderly-population trial should confirm those figures directly against the original journal articles before using them in patient-facing or clinical content.

What is more solidly established, independent of the exact trial numbers, is the regulatory outcome: eszopiclone was approved on December 15, 2004, as a sedative-hypnotic without a labeled duration restriction, which was a departure from prior practice in this drug class, according to publicly available FDA approval records.

How the label has changed since approval

2013 to 2014, dose reduction. The FDA reviewed impairment data across sedative-hypnotics and, following a similar move for zolpidem in 2013, recommended lower starting doses across the class. The FDA's zolpidem-specific safety communication is reported to have described the agency's blood-level and next-day-impairment reasoning in detail regarding how it approached this issue across the Z-drug class. Eszopiclone's own starting-dose guidance was similarly revised downward around this period; anyone relying on the exact current recommended starting dose should confirm it against the current FDA-approved label rather than this history page, since dosing guidance can be updated.

2019, boxed warning for complex sleep behaviors. In 2019 the FDA added a boxed warning to eszopiclone, zolpidem, and zaleplon covering rare but serious complex sleep behaviors, including sleepwalking, sleep-driving, and other activities performed while not fully awake, some of which resulted in serious injury or death across the drug class over an extended postmarketing surveillance period, per FDA safety communications. This page does not restate the exact case count from that communication; readers who need the precise figure should read the FDA notice directly, since restating a number from memory risks transcription error on a safety-critical fact. Eszopiclone is now contraindicated in patients with a prior complex sleep behavior episode on any sedative-hypnotic.

Generic entry. Eszopiclone lost U.S. market exclusivity in 2014, after which generic versions entered the market. Exact market-share and prescription-volume figures (peak annual prescriptions, generic uptake percentage, cumulative branded sales) that appeared in earlier drafts of this history could not be verified against a primary source in this review and have been removed rather than restated as precise numbers.

Hepatic impairment: a caution worth flagging explicitly

Case-level evidence has raised concern about eszopiclone-associated liver injury in patients with pre-existing chronic liver disease. A published case report describes acute liver injury attributed to eszopiclone in a patient with underlying chronic liver disease (case report, 2021). A single case report does not establish causation or incidence, but it is consistent with the general prescribing caution to use a lower maximum dose and closer monitoring in patients with hepatic impairment. This is a different consideration from the complex sleep behavior boxed warning and should not be conflated with it.

Eszopiclone compared with other Z-drugs: what's established and what isn't

Zaleplon's short half-life limits its evidence base to sleep-onset insomnia. Zolpidem immediate-release is also primarily positioned for sleep onset, and a recent narrative review of zolpidem's efficacy and side effects is a reasonable starting point for readers comparing the two drugs directly (zolpidem efficacy and side effects review, 2021). Eszopiclone's longer half-life is why it is more often discussed for both onset and maintenance insomnia, but "longer half-life supports both indications" is a pharmacokinetic inference, not a substitute for a specific trial showing superiority over another agent for maintenance insomnia. No claim in this article should be read as establishing that eszopiclone is more effective or safer overall than zolpidem, zaleplon, or non-drug treatment; the comparative trial evidence needed to make that claim was not available in the sources used for this draft.

Professional guideline bodies, including sleep medicine and general internal medicine organizations, have historically positioned cognitive behavioral therapy for insomnia (CBT-I) as a first-line approach, with pharmacologic options, including eszopiclone, considered for patients who do not respond adequately to CBT-I or cannot access it. Readers should confirm current guideline wording directly with the issuing organization, since guidelines are periodically updated and this article does not carry forward specific guideline citation numbers that could not be verified.

Corporate history

Sepracor Inc., founded in 1984 around chiral drug chemistry, developed and launched Lunesta. The company was acquired by Dainippon Sumitomo Pharma in 2009 and renamed Sunovion Pharmaceuticals in 2010. Sunovion continued to market branded Lunesta through patent expiration in 2014. Specific historical sales figures are not restated here because they could not be verified against a primary financial source within the material available for this review.

Evidence boundary: what this history does and does not establish

Established: Eszopiclone is the FDA-approved S-enantiomer of zopiclone, approved December 15, 2004, without a labeled duration restriction; it is a Schedule IV controlled substance; it now carries an FDA boxed warning for complex sleep behaviors (2019); and dosing guidance has been revised downward from the original approval doses.

Plausible but not established from the sources reviewed here: That eszopiclone's alpha-2/alpha-3 receptor selectivity translates into a clinically meaningful reduction in next-day impairment compared with specific benzodiazepine comparators; that eszopiclone is more effective than zolpidem or zaleplon for maintenance insomnia in head-to-head terms.

Not established, or requiring primary-source verification before repeating: Exact numeric trial results from the 2003 Krystal trial and related studies; exact case counts behind the 2019 boxed warning; exact historical prescription volumes and sales figures for Lunesta.

Decision framework: what eszopiclone's history should and should not change about a reader's choice

When to seek urgent care

Anyone who experiences an allergic reaction (swelling of the face or throat, difficulty breathing), engages in dangerous sleep-related behavior such as driving while not fully awake, or has signs of liver injury (jaundice, dark urine, right upper abdominal pain) while taking eszopiclone should seek urgent medical evaluation rather than waiting for a routine follow-up. This article does not provide individualized dosing or diagnostic guidance; those decisions require a clinician who knows the patient's full history.